Document is current

Article History

Received: 17 October 2024

Revised: 14 February 2025

Accepted: 11 March 2025

First Online: 25 March 2025

Competing interests

: DY reports leadership or fudiciary roles in other board, society, committee or advocacy group for Bayer and Specialised Therapeutics. JRZ reports grants or contracts from Bristol Myers Squibb, AstraZeneca, Pfizer, IQvia, Mylan, Ipsen, Eisai, Medtronic, MSD Oncology, Servier; consulting fees from Merck, Sharp & Dohme, Specialised Therapeutics, CEND, Deciphera, Revolution Medicine, FivePHusion, Genorbio, 1Global, Novotech, Alloplex Biotheapeutics Inc, NOUS Consulting and Oncology Republic; support for attending meetings and/or travel from MSD Oncology, ICON Group, PRAXIS; Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid from ICON group, Lipotex and PRAXIS; Stock or stock options from Biomarin, Ophthea, Amarin, Concert Pharmaceuticals, Frequency Therapeutics, Gilead, Madrigal Pharmaceuticals, UniQure, Zogenix, Orphazyme, Moderna Therapeutics, TWST, Novavax, Teladoc, Gilead Sciences, MSD Oncology and Viatris. JYB reports support for the present manuscript from InterSARC grant, NETSARC and LYRICAN + °; Consulting fees from Bayer and Novartis. ME reports Grants or contracts from institutional support from Novartis for the adjuvant GIST trial SSG XXII; Consulting fees from Consultant for Blueprint Medicines until 2021; Participation on a Data Safety Monitoring Board or Advisory Board as Chairman of the Data Management Board for IMPRESS Norway; Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as Chairman of the Ethical Advisory Board for SELNET. AI reports Grants or contracts from BAYER, ROCHE, ASTRAZENECA, MERCK, MSD and BMS; consulting fees from BAYER, ROCHE, ASTRAZENECA, MERCK, MSD and BMS. NS provided consultation or attended advisory boards for Boehringer Ingelheim, Cogent Biosciences, Ellipses Pharma, Incyte, Luszana; received research grants from Abbvie, Actuate Therapeutics, Amgen, Array, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol-Myers Squibb, Cantargia, CellCentric, Cogent Biosciences, Cresecendo Biologics, Cytovation, Deciphera, Dragonfly, Eli Lilly, Exelixis, Genentech, GlaxoSmithKline, IDRx, Immunocore, Incyte, InteRNA, Janssen, Kinnate Biopharma, Kling Biotherapeutics, Luszana, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Navire Pharma, Novartis, Numab Therapeutics, Pfizer, Relay Pharmaceuticals, Revolution Medicin, Roche, Sanofi, Seattle Genetics, Taiho, Takeda (all outside the submitted work, all payment to the Netherlands Cancer Institute). KB reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis; participation on a Data Safety Monitoring Board or Advisory Board for GSK, Bayer, NEC Oncoimmunity, Incyte. CG reports grants or contracts from study sponsor for costs of study conduct. JS reports support for the present manuscript from Bayer; grants or contracts from Roche, BMS, AZ, MSD, Pfizer, National Health and Medical Research Council, Australia; consulting fees from Detsamma Investments Pty Ltd as FivepHusion. HJ reports support for the present manuscript from Scandinavian Sarcoma Group; consulting fees from Orion Pharma andNeutron Therapeutics; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Deciphera Pharmaceuticals; patents planned, issued or pending from Sartar Therapeutics; participation on a Data Safety Monitoring Board or Advisory Board for Neutron Therapeutics, Orion Pharma and Maud Kuistila Foundation; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Orion Pharma; stock or stock options from Orion Pharma and Sartar Therapeutics. DE, SM, TP, VG, HG do not report any conflicts of interest.

: All participants provided written informed consent according to International Conference on Harmonization and Good Clinical Practices guidelines and national or local regulations. Lead ethics approval was granted by the Sydney Local Health District Human Research Ethics Committee (Protocol No X14‐0218 & HREC/14/RPAH/286) for the AGITG sites. The study was approved by the human research ethics committee of each participating country or institution. The study was performed in accordance with the Declaration of Helsinki.